Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mengdie Yuan

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The International Journal of Biostatistics|May 13, 2014
Semiparametric odds rate model for modeling short-term and long-term effects with application to a breast cancer genetic studyMengdie Yuan, Guoqing Diao
BMC Proceedings|March 1, 2012
Joint association analysis of bivariate quantitative and qualitative traitsMengdie Yuan, Guoqing Diao
Statistics in Medicine|May 13, 2017
On assessing bioequivalence and interchangeability between generics based on indirect comparisonsJiayin Zheng, Shein-Chung Chow, Mengdie Yuan
Journal of Biopharmaceutical Statistics|August 28, 2019
Simultaneous confidence interval methods for analytical similarity assessmentJiayin Zheng, Donglei Yin, Mengdie Yuan, et al.
Journal of Biopharmaceutical Statistics|January 22, 2013
Comparing the response rates for superiority, noninferiority and equivalence testing with multiple-to-one matched binary dataYi Tsong, Mengdie Yuan, Xiaoyu Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid TumorsLeigh Marcus, Lola A Fashoyin-Aje, Martha Donoghue, et al.
The Oncologist|May 11, 2021
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with SorafenibMay Tun Saung, Lorraine Pelosof, Sandra Casak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract CancerSandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The International Journal of Biostatistics|May 13, 2014
Semiparametric odds rate model for modeling short-term and long-term effects with application to a breast cancer genetic studyMengdie Yuan, Guoqing Diao
BMC Proceedings|March 1, 2012
Joint association analysis of bivariate quantitative and qualitative traitsMengdie Yuan, Guoqing Diao
Statistics in Medicine|May 13, 2017
On assessing bioequivalence and interchangeability between generics based on indirect comparisonsJiayin Zheng, Shein-Chung Chow, Mengdie Yuan
Journal of Biopharmaceutical Statistics|August 28, 2019
Simultaneous confidence interval methods for analytical similarity assessmentJiayin Zheng, Donglei Yin, Mengdie Yuan, et al.
Journal of Biopharmaceutical Statistics|January 22, 2013
Comparing the response rates for superiority, noninferiority and equivalence testing with multiple-to-one matched binary dataYi Tsong, Mengdie Yuan, Xiaoyu Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid TumorsLeigh Marcus, Lola A Fashoyin-Aje, Martha Donoghue, et al.
The Oncologist|May 11, 2021
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with SorafenibMay Tun Saung, Lorraine Pelosof, Sandra Casak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract CancerSandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Pageof 1